PURPOSE: To evaluate the tolerability of escalating doses of stereotactic body radiotherapy (SBRT) for primary treatment of @entity1358 ( @entity1358 ) in poor surgical candidates. @entity1 AND METHODS: Eligible @entity1 included those with clinically staged radiographic and or pathologically confirmed @entity1358 who had not undergone previous abdominal or pelvic radiotherapy. All @entity1 had comorbid medical conditions which precluded surgery. Median (range) @entity1 age was 77.6years (range 59-89) years and all @entity1 had Karnofsky Performance Status of    60. Median @entity5 volume was 57.9cm(3) (range 13.8-174.7cm(3)). Dose-limiting @entity137 (DLT) was defined as grade 3 or worse @entity344 by Common Terminology Criteria of Adverse Events (version 4). @entity5 response was assessed by imaging results using Response Evaluation Criteria In @entity5 (RECIST) measurement and percutaneous biopsy. RESULTS: A total of 19 @entity1 (13 @entity1 and 6 @entity1 ) were treated on protocol from June 2006 through August 2011. Groups of 3-6 @entity1 received 24, 32, 40, and 48Gy in 4 fractions. Median (range) follow-up was 13. 7months (5.9-34.7months). For possibly treatment-related acute @entity137 , one @entity1 developed grade 2 @entity1295 and one developed grade 4 duodenal ulcer. For possibly treatment-related late @entity137 , 2 @entity1 experienced grade 3 @entity8 ( @entity740 ), one reported grade 2 @entity322 and one developed grade 4 duodenal ulcer. Among the 15 @entity1 with evaluable response, 3 and 12 had partial response and stable disease, respectively, utilizing RECIST criteria. Among the 11 @entity1 who had post-SBRT biopsy, only one (9%) was negative on first biopsy and an additional one (9%) turned negative without further therapy on second biopsy. CONCLUSIONS: Dose escalation to 48Gy in 4 fractions has been achieved successfully without dose-limiting @entity137 . A planned extension of this phase I trial is currently underway treating @entity1 to 60Gy in 3 fractions to further evaluate this experimental therapy.

Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'PATIENTS', 'men'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal toxicity'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity322 :: ('MESH:D014549', 'Disease') :: ['urinary incontinence'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Solid Tumors', 'Tumor'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal/genitourinary toxicity'] @entity740 :: ('MESH:D051436', 'Disease') :: ['worsening chronic kidney disease'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['localized renal cell carcinoma', 'RCC']
@entity1358 :: (MESH:D002292,Disease) :: ['localized renal cell carcinoma']
